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Introduction to Type 1 Diabetes Mellitus 
 Type 1 diabetes mellitus (DM) is presumably caused by an immunological or 
viral cumulative destruction of the β cells of the pancreas.  The β cell eradication leads to 
a complete or near complete inability to produce endogenous insulin 1, 2. Without insulin, 
significant amounts of glucose cannot be absorbed by cells and used in metabolic 
processes. 
 Insulin is a hormone that regulates glucose uptake in skeletal and cardiac muscle 
cells and adipose tissue by causing insertion of glucose transporter 4 (GLUT4) on cellular 
membranes. GLUT4 is not stimulated in type 1 diabetes unless synthetic (recombinant) 
insulin is present. GLUT1 and 3 are not insulin responsive and uptake glucose at a basal 
rate in red blood cells and neural tissue, respectively. GLUT2 is responsive after meals 
and uptakes glucose in the liver and pancreas for glycogen storage 55. 
Type one DM presents with polyuria (frequent urination), ketonuria (ketone 
bodies in the urine), polydipsia (increased thirst), weight loss, hunger, and mood swings. 
In 77.1% of new adolescent diagnoses, the patient also presents with diabetic 
ketoacidosis (DKA) 28. In the past, type 1 DM was known as “juvenile diabetes” because 
it was primarily diagnosed in children, with diagnoses peaking between 8-12 years of 
age. Increasing numbers of diagnoses in teens and adults has lessened use of the term(in 
fact, the only organization to still use the term is the Juvenile Diabetes Research 
Foundation [JDRF]. JDRF was founded in 1970, and has become a cornerstone of the 
type 1 research community 29). Initial diagnosis is made by a fasting fingerstick blood 
glucose test that reads greater than 126 mg/dL, a diminished glucose tolerance, or a 
hemoglobin A1c blood test (HbA1c) of greater than 6.5% 23. HbA1c is a measurement of 
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the percentage of circulating glycated hemoglobin, which can be equated to an estimation 
of blood glucose levels over the past three months 34.   
 In untreated type 1 DM, cells cannot maintain homeostatic glucose uptake,35,due 
to lack of GLUT4 stimulation to insert on cellular membranes. The body then releases 
glucagon as a counter regulatory measure in response to decreased insulin reactions on 
adipocyte and myocyte membranes 37, a reaction also triggered nonpathologically by 
hypoglycemia. Glucagon releases hepatic-origin glucose through glycolysis and 
gluconeogenesis. Due to the lack of insulin, the cells still cannot uptake the glucose 30. 
The body then turns to other sources of energy. Adipocytic free fatty acids are broken 
down by β oxidation into acetoacetate and β-hydroxybutarate. The body uses β-
hydroxybutarate as energy when it cannot access glucose, but the presence of ketone 
bodies acidifies the blood. The bicarbonate buffering system soon becomes 
overwhelmed, blood pressure drops, heart rate increases, and a type of respiratory 
alkalosis, known as Kussmaul breathing (rapid deep breathing that reduces blood CO2 
and acidosis 30 ), begins. If not corrected through careful administration of intravenous 
(IV) insulin- and, in severe cases of acidosis, bicarbonate- DKA may result in coma or 
death.  Late or incorrect diagnosis of type 1 DM can be life threatening. In fact, the 
Center for Disease Control (CDC) reported 2,417 deaths annually from DKA, 
approximately 17.3 deaths per every 100,000 diabetics 32. Up to a third of DKA deaths 
occur in individuals with no history of ketoacidosis 33. 
Polyuria, a symptom of untreated type 1 DM, is caused by lack of glucose 
reuptake by the kidneys. Under non-pathological circumstances, glucose is completely 
reabsorbed in the renal tubules, but in hyperglycemia or untreated diabetes, glucose 
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transporters are saturated, and glucose is passed out of the body in urine. The high 
glucose concentration in the renal filtrate keeps water from being reabsorbed by 
aquaporins in the kidney and going against its concentration gradient. Because of the high 
osmolarity of the filtrate, there is a greater urine volume, higher frequency of urination, 
and polydipsia 27.  
 
Treatment of 
Type 1 DM 
 Type 1 












DNA of E. coli 
and yeast cells 4, 5, 
Fig. 1: Diagram of amino acid sequence of endogenous human insulin 
(top) and insulin Lispro (Humalog). (Top- Eli Lilly and Company. Amino 
Acid Sequence of U-100 Insulin Lispro (Humalog). Digital image. Prescribing 
Information. Eli Lilly and Company, Nov. 2015. Web. 11 Feb. 2016. Lower- 
McCance, Kathryn L., and Sue E. Huether. Pathophysiology: The Biologic Basis 
for Disease in Adults and Children. 5th ed. Maryland Heights: Mosby, MO. 
Print.) Both human and Lispro insulin have a molecular formula of 
C257H389N65O77S6 and a molecular weight of 5,808 grams/mol 
49. The 
cysteine bonds are anchored on the same amino acids (AA), as well. The 
difference lies in B-28 and B-29 (highlighted on Lispro). They switch 
places from human to Lispro sequences, allowing Lispro to break into 
monomers for more rapid, human insulin-like absorption 50. Endogenous 
proinsulin (insulin precursor) has a C-peptide that is cleaved to form active 
insulin. Synthetic insulins do not possess a C-peptide in any state 55. 
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11. Typically, short-acting insulin lispro (Humalog, Eli Lilly) or aspart (Novolog, Novo 
Nordisk) 4, 5 are used in conjunction with basal insulin such as glargine (Lantus, Sanofi 
Diabetes) 11 or detemir (Levemir, Novo Nordisk) 8. The U.S. Food and Drug 
Administration (FDA) approved a novel basal insulin degludec (Tresiba, Novo Nordisk) 
in September 2015 10.  
The biggest difference between Tresiba and Lantus or Levemir is that Tresiba has 
been found to be effective for at least 42 hours. Alan Moses, Novo Nordisk’s Chief 
Medical Officer, claims that participants in Tresiba’s clinical studies asked for the study 
to be ended after this point, as they were bed-bound for the purposes of isolating Trisiba’s 
Fig. 2: Insulin action profiles of short-acting insulin Lispro (Humalog, Eli Lilly), 
Aspart (Novolog, Novo Nordisk), and basal insulin Glargine (Lantus, Sanofi 
Diabetes), and Detemir (Levemir, Novo Nordisk) 4, 5, 11. Lispro and Aspart both 
begin working within 15 minutes of injection and are completely metabolized after 
3-4 hours. Glargine works at a basal level for 24 hours, whereas Detemir is 
metabolized after 22 hours in the bloodstream 18. Adapted from Chase, H. Peter., 
MD. "Chapter 8- Insulin: Types And Activity. " Understanding Diabetes. 11th ed. 
Denver, CO: Barbara Davis Center for Childhood Diabetes, University of Colorado 
Health Sciences Center, 2002. 65-76. Print. 
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effects on blood glucose 13. He believes Tresiba could be injected for use as basal insulin 
once every other day, as opposed to traditional once-a-day Lantus or Levemir injections 
11, but Novo Nordisk chose not to seek FDA approval for an unorthodox treatment 
schedule and is currently prescribed for once-daily use 13. Tresiba’s relative activity 
remains even for about 30 hours after injection, and then decreases linearly as the time 
after injection approaches 42 hours 60.  
Since it is only approved for a 24-hour gap between doses, Tresiba’s single clear 
clinical advantage over glargine and detemir is a 25% reduction in incidence of overnight 
hypoglycemia 10, because Lantus has been found to cause regular occurrence of nocturnal 
hypoglycemia in individual clinical cases and larger studies 15. Some people use a lesser 
does of Tresiba than they would of Lantus, but the mechanism of hypoglycemia reduction 
is currently unclear 10. (It is worth noting that most major health insurance companies do 
not currently cover the costs of Tresiba. Novo Nordisk, the parent company, does offer 
patients a card that reduces the cost of prescriptions to $15 for 24 months. The card does 
not seem to be accepted by all pharmacies, however 60. )  
Nocturnal hypoglycemia in type 1 DM is frequently caused by an increase in 
insulin sensitivity beginning around midnight and lasting about three hours 37. Lantus is a 
flat-rate insulin that does not decrease during those hours 11, thus potentially causing the 
hypoglycemia. A study using continuous glucose monitoring technology found that up to 
75% of severe hypoglycemia episodes occur overnight 57. Nocturnal “hypos” cause poor 
daytime control of blood glucose, as the body naturally rebounds in the morning to a high 
level of circulating glucose 17. This ricochet is known as the Somogyi effect, and occurs 
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in part because of a release of epinephrine and some glucagon that allows the liver to 
release glucose into the bloodstream 14 by means of gluconeogenesis.  
Conversely, an overnight circadian release of growth hormone (GH) frequently 
causes “fasting hyperglycemia,” also known as dawn phenomenon. GH also promotes 
hepatic gluconeogenesis. In non-diabetics, the release of GH and glucose is countered by 
endogenous insulin release 
27, but diabetic patients 
have a significantly harder 
time countering this 
phenomenon, due to their 
ever-changing insulin 
requirements. Current 
treatments for dawn 
phenomenon range from 
sharply increasing basal 
insulin about one hour 
before waking to early 
morning workouts to 
low/no carbohydrate 
breakfasts and “pre-
bolusing.” Humalog insulin 
takes fifteen minutes to 
begin working, and 
Fig. 3: Glucose Uptake in Normal Cells and in Diabetes. Chase, H. 
Peter, MD. “What is Diabetes?” Understanding Diabetes. 11th ed. 
Denver. CO: Barbara Davis Center for Childhood Diabetes, 
University of Colorado Health Sciences Center, 2002. 11. Print.  
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Novolog takes five to ten. Patients are often encouraged to “pre-bolus” by injecting their 
insulin up to thirty minutes before eating 34. 
It is important to understand that not all patients with type 1 DM experience 
nocturnal hypoglycemia, the Somogyi effect, or dawn phenomenon. Those who do will 
experience it to varying degrees, and the effects will change from day to day, depending 
on variation in daily exercise, diet, sleep, emotions, and stress, among other variables and 
events.  
These variables lead many diabetic patients to use insulin pumps. An insulin 
pump is essentially a small computer attached to a reservoir of fast-acting insulin- 
Humalog or Novolog- attached via a hollow plastic cord to a six or nine millimeter 
subcutaneous plastic or steel catheter, usually inserted in the hips, abdomen, or thigh 39. 
The pump delivers insulin in boluses (for carbohydrate intake and hyperglycemia 
correction 40) and at constant basal (user-programmed hourly rates of insulin delivery, 
accurate to 0.0001 mL in most pumps 39). The physician or patient programs the pump 
with varying insulin to carbohydrate ratios, basal insulin rates, target blood glucose 
levels, and insulin sensitivities. For a bolus, the user inputs blood glucose and 
carbohydrates ingested, and the pump calculates the needed insulin and delivers it after 
user confirmation of the amount (a program known colloquially as a wizard 56). The 
pump automatically administers basal insulin. 
Patients using syringe injections or pre-filled insulin pens generally administer a 
bolus of long-lasting basal insulin- typically Lantus or Levemir- once every 24 hours. 
Short acting insulin (Humalog or Novolog) doses are manually calculated and injected 
several times a day. Injections are often associated with a higher risk of incorrect 
Markert  9 
bolusing or insulin usage, eg: taking 30 units of short acting Humalog rather than 30 units 
of long-lasting Lantus. Although this can be corrected if the patient quickly realizes their 
mistake, severe hypo- or hyperglycemia could result from incorrect insulin usage 
One recent advance in preventing nocturnal hypoglycemia is the Medtronic 
Minimed 530G System, which is comprised of an insulin pump that communicates 
wirelessly with its paired continuous glucose monitor (CGM) 56 (a subcutaneous catheter 
that measures blood glucose levels of interstitial fluid 55). The 530G comes with 
“Threshold Suspend- SmartGuard” programming that prompts the pump to cease all 
insulin delivery when the CGM registers a blood glucose level below a user-set number 
56. This closed loop system is especially useful for small children or people who routinely 
suffer from nocturnal hypoglycemia. 
Tandem Diabetes, an up-and-coming insulin pump company, has a similar 
system, incorporating a Tandem tslim insulin pump and a Dexcom G5 CGM into a single 
device. The CGM, rather than transmitting information to a separate receiver, sends 
blood glucose readings directly to the tslim pump 60. 
In what seems to be an effort to push Tandem out of the market, Medtronic and 
United Healthcare, a major insurance provider, signed a deal to make Minimed United’s 
preferred insulin pump. Beginning July 1, 2016, adult diabetics covered by United will be 
required to switch to Minimed pumps when their current pump reaches the end of its 
warranty. Patients will not be provided insurance for Tandem, Animas, or Roche insulin 
pumps, although it is unclear how coverage for the Omnipod pump may change 60, 67. 
It is worth noting an independent third party called openAPS has created an 
approximately 200-line code that functions as a closed loop system for overnight blood 
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glucose control. The code is only promoted for overnight control, as the programming 
and variables are simpler when the patient isn’t eating or exercising. openAPS is free for 
use and open source, but requires the user to build their own artificial pancreas from a 
Minimed pump, CGM, Raspberry Pi computer, and various other small pieces of 
hardware. The organization’s hope is that manufacturers and type 1 DM patients alike 
will use and better the code for the better of all 61.  
The insulin receptor pathway is the same, regardless of insulin analog type or 
injection method. Cells have two-part insulin receptor that is part of the receptor tyrosine 
kinase (RTK) family. Insulin, insulin-like growth factor 1 (IGF-1), and IGF-2 activate the 
receptor and cause dimerization 47. The receptor then autophosphorylates itself with 
Fig. 4: Insulin receptor pathway in cells. Navratil, Amy. "MHA- Receptor Tyrosine 
Kinases." Mechanisms of Hormone Action. Laramie. Mar. 2016. Lecture. 
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tyrosine residues from its own β subunit, which allows a Grb protein to bind on to it. The 
Grb has a special region called an SH2 domain that binds primarily to phosphorylated 
RTKs. Son of Sevenless (SOS) protein binds to the other end of Grb at the SH3 domain. 
SOS can then activate Ras-MAP phosphorylation cascades to initiate insulin-related gene 
transcription 51.  PI-3 kinase (PI-3K) is another protein that binds to the insulin receptor 
with a SH2 domain. PI-3K phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) 
to PIP3 (PI 3,4,5-triphosphate), which begins a phosphorylation cascade and ultimately 
activates glycogen synthase kinase 3 (GSK-3) by phosphorylation. When phosphorylated, 
GSK-3 cannot deactivate glycogen synthase, thus allowing cells to uptake glucose for 
conversion to glycogen 52 and reducing circulating blood glucose levels. After this 
process, insulin receptors and molecules are typically endocytosed by the cell and 
degraded 51. 
 
Part II: Exercise and Diabetes 
 Alpha (α) cells produce glucagon, a polypeptide that stimulates liver-mediated 
glycolysis in response to low blood sugar. Although α cells are not destroyed with the 
onset of type 1 DM, their function is compromised by decreased α/ β cell communication 
3. As a result of this, there is not an innate physiological counter to hypoglycemia (<70 
mg/dL or 3.89 mmol/L) in patients with type 1 DM. β cell loss also increases with time 
from the onset of type 1 DM, so any remaining α cell communication or response to 
hypoglycemia drastically decreases 14.  
 Exercise can cause different reactions in relation to blood glucose concentration, 
depending on duration and intensity. High intensity aerobic workouts, such as cardio or 
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high intensity interval training (HIIT), cause blood glucose to drop, with or without the 
presence of active or “on board” exogenous insulin.  
Lower intensity exercise, weight lifting or sprints, for example, can cause blood 
glucose to rise7. This can cause problems for the patient in terms of diabetic management 
during exercise, as patients often over-compensate for an expected glucose drop by eating 
carbohydrates and taking a reduced bolus amount of insulin (or no insulin at all) in 
anticipation of a sharp blood glucose drop. Patients, especially those who are young or 
newly diagnosed, often do not understand the mechanisms of glycolysis in anaerobic 
exercise 34. 
Anaerobic exercise is usually an explosive, short-distance activity, such as 
sprinting, jumping, and “maxing out” while weight lifting. It is characterized by fast, 
strong muscle contractions. The phosphagen system produces much of the needed 
energy. Creatine phosphate is catalyzed by creatine kinase to donate a phosphate to 
adenosine diphosphate (ADP) to make adenosine triphosphate (ATP), the primary energy 






ADP + H+ 
Fig. 5: Creatine phosphate and ADP + H+ react via creatine kinase to form creatine 
and adenosine triphosphate (ATP). Adapted from Brooks, George A., and Thomas 
D. Fahey. Exercise Physiology: Human Bioenergetics and Its Applications. New 
York: Wiley, 1984. Print 
Markert  13 
require carbohydrates, fats, or oxygen, making it the first source of energy during 
exercise19.  
 After about ten seconds, energy production moves to anaerobic glycolysis, 


































Fig. 6: Direct ATP generation from glycolysis. One molecule of glucose travels down the 
pathway, ultimately generating 1 molecule of nicotinamide adenine dinucleotide (NADH), 4 
molecules of ATP, and 2 molecules of pyruvate. The pyruvate enters lactic acid fermentation or 
the citric acid cycle and continues to create energy. Adapted from McCance, Kathryn L., and 
Sue E. Huether. Pathophysiology: The Biologic Basis for Disease in Adults and Children. 5th 
ed. Maryland Heights: Mosby, MO. Print. 
  
ATP generated 
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circulating blood glucose and glycogen stored in myocytes are catabolized to pyruvate 
(Fig. 6) 19. One molecule of glucose can generate two molecules of pyruvate, which then 
enters the aerobic citric acid cycle or undergoes anaerobic conversion to lactic 
acid through fermentation. 
 Anaerobic exercise also increases levels of catecholamines, growth hormone, and 
cortisol in the bloodstream all of which inhibit insulin 42 through disruption of cellular 
signaling pathways. In a rat model, catecholamines actually decreased the number of 
insulin receptors on the cellular surface 44. Growth hormone breaks up PI-3 kinases, 
which- when dimerized with themselves- are used as part of the insulin signaling 
pathway for glucose uptake 43. 
 When basal insulin is reduced or bolus is reduced in anticipation of blood glucose 
drop during exercise, blood glucose can end up rising at rates of more than 2-3 
mg/dL/minute if insulin rates are reduced too greatly, blood or urine ketones are present, 
or exercise is primarily anaerobic 16, 47. Given that blood glucose levels optimally remain 
below 126 mg/dL, a thirty-minute weight workout could potentially raise blood glucose 
by 90 mg/dL and catapult athletes out of their recommended range.  
 Exercising with hyperglycemia is strongly discouraged, because glucose begins to 
spill over into urine in the form of ketones when blood glucose levels reach about 175 
mg/dL. It is recommended that ketone levels be tested by fingerstick blood test or urine 
test anytime fasting blood glucose is > 240 mg/dL, daytime blood glucose is > 300 
mg/dL, the patient vomits, or is otherwise ill 47. Extra Humalog or Novolog insulin is 
generally administered for mild to moderate ketones (0.6-3.0 mmol/L). Although insulin 
brings blood glucose down much faster when combined with exercise, exercise also 
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encourages acidosis. Significant water is lost through sweat, so the resultant dehydration 
increases the concentration of acidic compounds in the body 45, namely β-hydroxybuteric 
acid in the blood and acetoacetic acid in the urine 47. Patients in DKA can often be 
identified by their fruity, acetone breath, which is comparable to the smell of Juicy Fruit 
chewing gum. 
Blood/Urine Ketone Level (mmol/L) Suggested Treatment 
0-0.6 Within normal range. 
0.6-1.0 Mild elevation, drink fluid. 
1.0-3.0 Moderate elevation, take fast-acting insulin 
such as Humalog or Novolog, drink fluids, 
call physician. 




While anaerobic lactic acid fermentation indirectly generates a small amount of 
energy, as does the citric acid cycle, most ATP (36 molecules) is generated through the 
aerobic electron transport chain 19. A series of four intramembranous mitochondrial 
complexes (NADH dehydrogenase, succinate dehydrogenase, cytochrome c reductase, 
and cytochrome c oxidase) pump hydrogen ions against their concentration gradients to 
create an electrochemical gradient 25.  NADH is oxidized to form this proton gradient, 
and oxygen is used as the oxidizing electron receptor in the cytochrome c oxidase 
reaction 53. Oxygen is reduced with two hydrogen ions to form water and drive the 
Table 1: Diagram of blood/urine ketone levels and suggested treatment, adapted from Chase, 
H. Peter. "Chapter 5: Ketone Testing." Understanding Diabetes. Denver, CO: Barbara Davis 
Center for Childhood Diabetes, U of Colorado Health Sciences Center, 2002. 29-34. Print. 
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gradient allowing the ATP synthase F1 subunit to rotate about the F0 subunit and 
synthesize ATP from ADP and phosphate 38.  
As glycolysis begins to produce ATP, aerobic mitochondrial respiration also 
begins producing energy from pyruvate. Mitochondrial respiration is the dominant form 
of energy genesis, responsible for about 60% of energy production within five minutes of 
initiating constant exercise 24.  It can produce far more energy than any of the anaerobic 
energy generation pathways, usually estimated around 38 ATP in total, 2 ATP from 
glycolysis, 2 ATP from the citric acid cycle, and 34 from the electron transport chain 38.  
An endurance event, such as long-term backpacking, primarily utilizes aerobic 
respiration. Aerobic exercise is categorized as “moderate-long lengths of motion at 50-
80% of an individual’s maximum heart rate” 54. There is a low rate of aerobic ATP 
generation, but it can be sustained for far longer than glycolysis or the phosphagen 
system. However, the mitochondria still draw on blood glucose reserves, as well as 
myocytic and hepatic glycogen stores, adipocytes, and intramuscular fat reserves 19.  
This makes endurance events still harder for a diabetic to manage. During 
moderate-intensity exercise, the amount of actively circulating blood glucose increases 
from about 4 grams (for a 68 kg person) to 20-40 grams 7, while usage is about 1-1.5 
grams of glucose per kg of body mass per minute 16.  The circulating glucose level must 
be maintained to prevent hypoglycemia. In an physically fit person without type 1 DM, 
the body can produce up to 10 mg of glucose per kg of body mass per minute 7. Since 
type 1 diabetics lack the α/ β cell communication that produces glucagon as well as the 
insulin-mediated regulation of other reactions, aerobic exercise can quickly cause 
hypoglycemia, as glugoneogenesis and glycogenolysis are slower energy generation 
Markert  17 
processes than circulating blood glucose uptake 16. The hypoglycemia caused by exercise 
may have a lingering metabolic effect and depress blood glucose for several hours after 
the end of the workout - or even overnight 17 which can be especially problematic when 
interacting with Lantus-mediated nocturnal hypoglycemia or poorly adjusted basal rates.  
In fact, the American Diabetes Association (ADA) recommends exercising after eating a 
meal or snack and following the activity up with at least 15 grams of carbohydrate within 
30-120 minutes of ending the exercise. The ADA also proposes changing medications 
and insulin rates and ratios if “hypoglycemia regularly interferes with [the] exercise 
routine” 41.  
A Finnish study found that a 30-minute workout equivalent to “moderate walking 
or low-intensity running” did not significantly decrease blood glucose when trial 
participants injected only 70% of their normal daily basal insulin. It is also worth noting 
the trial used novel insulin degludec (Tresiba, Novo Nordisk) rather than the well-
established basal insulins glargine (Lantus, Sanofi Diabetes) or detemir (Levemir, Novo 
Nordisk) 8. However, basal insulin reduction varies between patients, anywhere from 
80% to 30% of rates. Complete suspension of insulin administration is also used, but 
generally not for more than 60-90 minutes, at most, as blood glucose levels will quickly 
rise after cessation of exercise. Without any active insulin, it takes longer to bring blood 
glucose back into a recommended range 34. 
 
Bringing Diabetes into the Backcountry 
 As Henry David Thoreau said, “I took a walk in the woods and came out taller 
than the trees.” People have backpacked since they first had something to carry, but the 
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sport has recently gathered attention in the light of movies and novels such as Cheryl 
Strayed’s Wild, Bill Bryson’s A Walk In The Woods, and Frank Delaney’s Shannon. 
Especially now, with increasing urbanization and technological advances, 
backpacking is becoming a way to escape the modern world and reconnect with one’s 
sense of being or identity. Forays into the woods and mountains range in length from a 
one-night, ten-mile loop to the six-month long Appalachian Trail, spanning 14 states and 
2,200 miles 58.   
Despite possible medical and logistical concerns, diabetics still feel the pull of the 
wilderness. Children’s summer camps funded by the American Diabetes Association host 
night and week-long backpacking trips, complete with physicians, dieticians, and medical 
supplies 59. The Appalachian Trail Conservancy keeps registers of long-distance hikers 
and certain other subsets, including diabetic hikers. Although registration is not required, 
the rosters are made available at request to interested hikers 58.  
Equipment requirements are fairly standard. Beyond clothing and a sleeping bag, 
most backpackers bring a tent with a waterproof fly, camp stove, fuel (such as propane), 
matches, a first aid kit, a hatchet or saw-blade knife, map, headlamp, dish and utensils, 
pot, bear canister, rope, lantern, and toiletries. Diabetics need to bring along all supplies- 
infusion sets, lancets, syringes, glucometers, batteries, insulin (typically kept in a cooling 
wallet or coat pocket, depending on weather), glucagon, sharps container, alcohol swabs, 
and glucose tabs- that would normally be used during an equivalent time period, as well 
as spare and back-up parts in case of equipment failure or emergency. 
Nonetheless, the true variant in backpacking supplies is food. The quantity needed 
depends on the length and intensity of the hike, with an average expenditure of 3000-
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5000 calories per day 62, usually about 1.5-2.5 pounds of food per day 63. Hikers typically 
pack calorie-dense foods, such as nuts, cheese, dried fruit, M&Ms, dehydrated rice or 
pasta, and dried meat. Vegetables and fresh food are typically reserved for short trips or 
used within the first few days of a long-distance hike. During trips lasting more than a 
week or two, hikers often mail care packages to general delivery or go grocery shopping 
in towns along their route. 
Despite such nutrient-dense diets, most backpackers do not manage to intake a 
sufficient number of calories, averaging a daily 2,722 calorie deficit. 62. Similar energy 
deficiency trends are noted in other long-distance sports, such as ultra-endurance cycling 
64 and sled dog racing 65. Studies of both cyclists and dogsled racers also found moderate 
dehydration was common 64, 65. 
Caloric deficit should not affect blood glucose levels, as long as insulin ratios are 
adjusted accordingly 8. The only major stimulus of blood glucose change during chronic 
hiking is the activity itself. Pre-event physical fitness plays into the effect of exercise on 
blood glucose. Typically, patients with a higher level of fitness require less basal and 
bolus insulin and do not suffer large blood glucose decreases when compared to less fit 
peers, although this is not universal 65. Carla Cox (PhD, RD, CDE) recommends cutting 
boluses in half if they are within two hours of strenuous exercise, decreasing basal to 75-
30% of normal about ninety minutes before activity, and keeping basal reduced overnight 
if blood glucose is less than 130 mg/dL before going to bed. Although this greatly 
reduces hypoglycemic episodes, or “lows”, it does not eliminate them. Dr. Cox 
recommends treating mid-hike lows with a combination of carbohydrate and protein- 
such as Lärabars or fruit snacks with string cheese- to quickly raise blood glucose and 
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then sustain the increase 65. (An object of note: up to 55% of severe hypoglycemic 
episodes and 43% of all hypoglycemic episodes occur overnight, and nocturnal 
hypoglycemic episodes last an average of 86 minutes70.) It is also recommended to eat 
carbohydrate-heavy meals for dinner, using whole grains, if possible, to slow digestion 68. 
In fact, 50-60% of daily calories while backpacking are recommended to be 
carbohydrates 69.  
As one’s body adjusts to the physical demands of backpacking, blood glucose, 
insulin requirements, and energy requirements normalize 7, 62. With stabilization and 
practice, management of diabetes on the trail becomes easier. Generally, by the end of the 
first week on the trail, diabetics can usually keep a majority of blood glucose values in-
range (80-180 mg/dL 22) with decreased total daily insulin, sometimes using only 70% or 
less of their usual insulin 62,66. 
After a backpacking trip ends, insulin and dietary requirements return to near pre-
hike levels, unless a similar amount of physical activity is sustained or the patient has 
significant weight loss 8, 65, 66. 
 
Conclusion 
Type 1 diabetes mellitus is a chronic disease of indeterminate origin- likely parts 
genetic, epigenetic, and viral, resulting in destruction of pancreatic β cells.  Currently, 
treatment consists of lifelong blood glucose monitoring and subcutaneous injection of 
synthetic insulin, with care options ranging from using fast-acting insulins lispro and 
aspart in insulin pumps to combined lispro or aspart with basal rate insulins glargine, 
detemir, or degludac.  
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Management of the disease is difficult, especially when exercising. Anaerobic 
exercise has a tendency to raise blood glucose through glycolysis and cortisol hormone 
mechanisms. Aerobic exercise is primarily dependant on the electron transport chain and 
draws on blood glucose reserves, causing a drop in blood glucose levels. 
The best treatment for type 1 DM and prolonged aerobic exercise seems to be 
continuous glucose monitoring alongside great daily insulin reduction, whether injections  
or an insulin pump are used. Lantus (insulin glargine) seems to be counter indicated in 
backpacking 







may be a more 
appropriate 
choice, although 
this has not been 
studied. With an insulin pump, basal and bolus insulin ratios can easily be reduced and 
changed from day to day. 
Advanced meal planning, with consideration for carb-heavy dinners and snacks, is 
necessary. Snacks for mid-hike and overnight hypoglycemia should be accounted for 
Fig. 7: American Diabetes Association Camp Montana collegiate 
backpackers and medical staff on the Beaten Path, Montana. Personal 
photo by author, 5 Aug. 2013.  
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during planning. Extra snacks should be allotted for the first several days of a 
backpacking trip, as the patient learns how their body reacts to long-duration, aerobic 
exercise.  
Insulin rates reduce with acclimatization to physical activity, and blood glucose 
stabilizes concurrently. Nonetheless, proper nutrition and hydration are key to the 
maintenance of health while in the backcountry, especially as long-distance athletes tend 
to suffer from caloric deficits and dehydration.  
However, there is no reason for type 1 diabetics to avoid the great outdoors. After 
a steep initial learning curve with appropriate precautions and monitoring, a diabetic may 
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